

CITATION REPORT

List of articles citing

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

DOI: 10.1161/jaha.116.003725

Journal of the American Heart Association, 2016, 5, .

Source: <https://exaly.com/paper-pdf/65269514/citation-report.pdf>

Version: 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
297	"Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation. 2016 , 116, 587-9		46
296	Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation. 2016 , 38, 2477-2488		21
295	Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis. 2017 , 17, 15		8
294	Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017 , 48, 970-976	6.7	74
293	Dabigatran Etxilate: A Review in Nonvalvular Atrial Fibrillation. 2017 , 77, 331-344		12
292	Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). 2017 , 12, 419-422		9
291	Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation. 2017 , 10,		22
290	Abnormal uterine bleeding in women receiving direct oral anticoagulants for the treatment of venous thromboembolism. 2017 , 93-95, 1-5		17
289	Evaluation of Apixaban for the Treatment of Nonvalvular Atrial Fibrillation With Regard to Dosing and Safety in a Community Hospital. 2017 , 33, 140-145		2
288	Risk of Gastrointestinal Bleeding in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta-analysis. 2017 , 15, 1674-1683.e3		84
287	Kommentar zu den 2016 Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zum Management von Vorhofflimmern. 2017 , 11, 193-204		11
286	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1595-1604	2.5	42
285	Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1745-1754	2.5	52
284	Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. 2017 , 26, 2102-2110		9
283	Comparative risk of major bleeding with new oral anticoagulants (NOACs) and phenprocoumon in patients with atrial fibrillation: a post-marketing surveillance study. 2017 , 106, 618-628		41
282	Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. 2017 , 376, 1627-1636		264
281	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. 2017 , 34, 357-377		10

280	The Year in Cardiology 2016: arrhythmias and cardiac implantable electronic devices. 2017 , 38, 238-246		1
279	Temporal Trends in the Use and Comparative Effectiveness of Direct Oral Anticoagulant Agents Versus Warfarin for Nonvalvular Atrial Fibrillation: A Canadian Population-Based Study. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	35
278	Association Between Use of Antithrombotic Medication and Hematuria-Related Complications. 2017 , 318, 1260-1271		21
277	Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. 2019 , 26, 106-112		6
276	Discovery methods of coagulation-inhibiting drugs. 2017 , 12, 1195-1205		14
275	Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation. 2017 , 34, 2274-2294		4
274	Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review. 2017 , 12, 554-560		11
273	Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1955-1963	2.5	30
272	Number needed to treat for direct oral anticoagulants over warfarin in atrial fibrillation. 2017 , 149, 275-276		
271	Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making. <i>International Journal of Cardiology</i> , 2017 , 245, 174-177	3.2	7
270	Number needed to treat for direct oral anticoagulants over warfarin in atrial fibrillation. 2017 , 149, 275-276		
269	Clinical implications, benefits and pitfalls of using and reversing non-vitamin K antagonist oral anticoagulants. 2017 , 10, 833-845		1
268	Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased Prescribing in Atrial Fibrillation Between 2012-2015: A Study from the Norwegian Prescription Database. 2017 , 34, 635-645		20
267	Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2017 , 48, 2494-2503	6.7	130
266	The representativeness of direct oral anticoagulant clinical trials to hospitalized patients with atrial fibrillation. 2017 , 73, 1427-1436		11
265	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. 2017 , 34, 2043-2057		13
264	Comparison of the CHADS-VASc, CHADS, HAS-BLED, ORBIT, and ATRIA Risk Scores in Predicting Non-Vitamin K Antagonist Oral Anticoagulants-Associated Bleeding in Patients With Atrial Fibrillation. 2017 , 120, 1549-1556		36
263	Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban. 2017 , 120, 1689-1695		20

262	New digital adherence devices could prevent millions of strokes from atrial fibrillation by the end of the next century. 2017 , 108, 46-50		4
261	Anticoagulant options in atrial fibrillation: When new treatments become standard practice. 2017 , 42, 29-35		
260	Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1583-1594	2.5	21
259	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. 2017 , 25, 551-558		20
258	A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban. <i>Current Medical Research and Opinion</i> , 2017 , 33, 1717-1723	2.5	3
257	Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2017 , 48, 2142-2149	6.7	70
256	A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017 , 3, 28-36 ^{6.4}		75
255	Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients. 2017 , 117, 1072-1082		102
254	Real-world Data and Recommended Dosage of Non-vitamin K Oral Anticoagulants for Korean Patients. 2017 , 47, 833-841		9
253	Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 980-988	1.9	23
252	Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017 , 23, 1191-1201	1.9	16
251	Non-valvular atrial fibrillation: impact of apixaban on patient outcomes. 2017 , 8, 121-131		5
250	Which of the Direct Oral Anticoagulants Is the Safest?: Based on Gastrointestinal Bleeding. 2017 , 69, 328		
249	Setting priorities in the health care sector - the case of oral anticoagulants in nonvalvular atrial fibrillation in Denmark. 2017 , 9, 617-627		5
248	Direct Oral Anticoagulants: A Quick Guide. 2017 , 12, 40-45		47
247	Warfarin. 2018 , 9-30		1
246	Atrial remodelling and function: implications for atrial fibrillation surgery. 2018 , 53, i2-i8		9
245	Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe. 2018 , 39, 2932-2941		19

244	Evidence and Indications for Percutaneous Closure of the Left Atrial Appendage. 2018 , 71, 700-702		1
243	Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	85
242	Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study. 2018 , 41, 576-585		10
241	A single institution's experience with using dabigatran, rivaroxaban and warfarin for prevention of thromboembolism in atrial fibrillation. 2018 , 27, 20-25		3
240	Atrial Fibrillation for the Neurologist: Preventing both Ischemic and Hemorrhagic Strokes. 2018 , 18, 6		4
239	Periprocedural Anticoagulation Management for Atrial Fibrillation Ablation: Current Knowledge and Future Directions. 2018 , 20, 3		6
238	Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: a matched cohort study. 2018 , 8, e019638		22
237	Outcome of Secondary Stroke Prevention in Patients Taking Non-Vitamin K Antagonist Oral Anticoagulants. 2018 , 27, 1174-1177		3
236	Real-world data on direct-acting oral anticoagulants. 2018 , 150, 161		
235	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. 2018 , 93, 1065-1073		18
234	Agreement between coding schemas used to identify bleeding-related hospitalizations in claims analyses of nonvalvular atrial fibrillation patients. 2018 , 41, 119-125		3
233	The Complementary Role of Real World Evidence: Focus on Oral Anticoagulants. 2018 , 27, 527-530		
232	Anticoagulation in atrial fibrillation with heart failure. 2018 , 23, 563-571		7
231	Safety and Effectiveness of Direct Oral Anticoagulants Versus Vitamin K Antagonists: Pilot Implementation of a Near-Real-Time Monitoring Program in Italy. <i>Journal of the American Heart Association</i> , 2018 , 7,	6	11
230	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. 2018 , 20, 420-428		38
229	Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. 2018 , 21, 244-253		12
228	Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention. 2018 , 20, 1-11		35
227	Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs. 2018 , 61, 3799-3822		13

226	Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries. <i>Current Medical Research and Opinion</i> , 2018 , 34, 55-63	2.5	7
225	Thromboembolic and Major Bleeding Events With Rivaroxaban Versus Warfarin Use in a Real-World Setting. 2018 , 52, 19-25		10
224	Real-world data on direct-acting oral anticoagulants. 2018 , 150, 161		1
223	A Retrospective Assessment of Postoperative Bleeding Complications in Anticoagulated Patients Following Mohs Micrographic Surgery. 2018 , 44, 504-511		21
222	Update on the use of direct oral anticoagulants for the prevention and treatment of thromboembolism. <i>Future Cardiology</i> , 2018 , 14, 89-99	1.3	
221	Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis. <i>Current Medical Research and Opinion</i> , 2018 , 34, 487-498	2.5	27
220	Anticoagulation in atrial fibrillation : Current evidence and guideline recommendations. 2018 , 43, 2-10		5
219	Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Stroke</i> , 2018 , 49, 98-106	6.7	67
218	Clinical characteristics and thromboembolic risk of atrial fibrillation patients with and without congestive heart failure. Results from the CRATF study. <i>Medicine (United States)</i> , 2018 , 97, e13074	1.8	7
217	Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. 2018 , 24, 261S-268S		1
216	[Oral anticoagulation therapy in the elderly population with atrial fibrillation. A review article]. 2018 , 53, 344-355		6
215	Association of Oral Anticoagulant Type With Risk of Dementia Among Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2018 , 7, e009561	6	23
214	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. <i>Stroke</i> , 2018 , 49, 2933-2944	6.7	157
213	Pharmacokinetics of new oral anticoagulants: implications for use in routine care. 2018 , 14, 1057-1069		21
212	Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. <i>PLoS ONE</i> , 2018 , 13, e0205989	3.7	34
211	The CHADSEVAsc Score Predicts Major Bleeding in Non-Valvular Atrial Fibrillation Patients Who Take Oral Anticoagulants. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	9
210	Predictors of Major Bleeding Among Working-Age Adults with Atrial Fibrillation: Evaluating the Effects of Potential Drug-drug Interactions and Switching from Warfarin to Non-vitamin K Oral Anticoagulants. 2018 , 32, 591-600		3
209	Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 1116-1127	1.9	22

208	In embolic stroke of undetermined source, rivaroxaban vs aspirin did not reduce recurrence and increased bleeding. 2018 , 169, JC32		
207	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018 , 24, 911-920	1.9	15
206	Rivaroxaban and apixaban induce clotting factor Xa fibrinolytic activity. 2018 , 16, 2276-2288		23
205	Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. 2018 , 7, 1063-1071		4
204	Effectiveness and Safety of Anticoagulants in Adults with Non-valvular Atrial Fibrillation and Concomitant Coronary/Peripheral Artery Disease. 2018 , 131, 1075-1085.e4		12
203	Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. <i>Thrombosis Research</i> , 2018 , 167, 113-118	8.2	18
202	Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 264, 85-90	3.2	10
201	Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1627-1634	2.5	14
200	Characteristics of Apixaban-Treated Patients, Evaluation of the Dose Prescribed, and the Persistence of Treatment: A Cohort Study in Catalonia. 2018 , 23, 494-501		8
199	Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation. 2018 , 115, 287-294		11
198	Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States. 2018 , 138, 1519-1529		225
197	Evidencia e indicaciones del cierre percutáneo de la orejuela izquierda. 2018 , 71, 700-702		3
196	NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. 2018 , 13, 1069-1075		10
195	Appropriateness of non-vitamin K antagonist oral anticoagulant dose in patients with atrial fibrillation in Israel: A population-based study. <i>Thrombosis Research</i> , 2018 , 169, 140-142	8.2	5
194	Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation. 2018 , 35, 859-869		2
193	Dabigatran, Rivaroxaban, and Warfarin in the Oldest Adults with Atrial Fibrillation in Taiwan. 2018 , 66, 1567-1574		15
192	LMU Munich: platelet inhibition novel aspects on platelet inhibition and function. 2018 , 107, 30-39		20
191	Risk of intracranial hemorrhage (RICH) in users of oral antithrombotic drugs: Nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , 2018 , 13, e0202575	3.7	28

190	Multiple spontaneous hemorrhages after commencing warfarin therapy. 2018 , 6, 2050313X18778380		1
189	Two-Year Outcomes of Anticoagulation for Acute Ischemic Stroke With Nonvalvular Atrial Fibrillation - SAMURAI-NVAF Study. 2018 , 82, 1935-1942		31
188	Comparative risks of bleeding, ischemic stroke and mortality with direct oral anticoagulants versus phenprocoumon in patients with atrial fibrillation. 2018 , 74, 1317-1325		17
187	A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation. <i>International Journal of Cardiology</i> , 2018 , 270, 167-171	3.2	16
186	Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 979-986	2.6	2
185	Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation. <i>International Journal of Cardiology</i> , 2018 , 268, 113-119	3.2	16
184	Trends and Variation in Oral Anticoagulant Choice in Patients with Atrial Fibrillation, 2010-2017. 2018 , 38, 907-920		107
183	Anticoagulantes orales directos frente a antagonistas de la vitamina K en pacientes con fibrilación auricular de la práctica clínica: revisión sistemática y metanálisis. 2019 , 72, 305-316		28
182	Effectiveness and Safety of Rivaroxaban 15 or 20 mg Versus Vitamin K Antagonists in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2019 , 50, 2469-2476	6.7	11
181	Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants. 2019 , 25, 1076029619870249 ⁵		
180	Idarucizumab administration in emergency situations: the Munich Registry of Reversal of Pradaxa [®] in clinical routine (MR REPAIR). 2019 , 266, 2807-2811		10
179	Impact of methodological choices on a meta-analysis of real-world evidence comparing non-vitamin-K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1867-1872	2.5	6
178	Stroke and Systemic Thromboembolism Prevention in People Living With Human Immunodeficiency Virus With Atrial Fibrillation: A Review of Its Implications for Clinical Practice. 2019 , 1, 245-255		2
177	Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS). <i>CNS Drugs</i> , 2019 , 33, 1223-1228	6.7	12
176	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database. 2019 , 10, 2042098619876737		3
175	Patient characteristics and stroke and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban and vitamin K antagonists: a Spanish real-world study. 2019 , 8, 1201-1212		2
174	Pylephlebitis treated with apixaban. 2019 , 47, 192-195		3
173	2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2019 , 16, e66-e93		176

172	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2019 , 74, 104-132		807
171	Safety of direct oral anticoagulants in real-world clinical practice: translating the trials to everyday clinical management. 2019 , 18, 187-209		15
170	Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population. 2019 , 19, 142		8
169	Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. 2019 , 3, 674-683		4
168	Re-evaluating Safety and Effectiveness of Dabigatran Versus Warfarin in a Nationwide Data Environment: A Prevalent New-User Design Study. <i>Drugs - Real World Outcomes</i> , 2019 , 6, 93-104	2.2	5
167	Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. <i>Current Medical Research and Opinion</i> , 2019 , 35, 1769-1776	2.5	2
166	Reversing Direct Oral Anticoagulants in Acute Intracranial Hemorrhage. 2019 , 39, e1-e8		0
165	Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients. 2019 , 67, 1662-1671		25
164	A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system. 2019 , 103, 43-46		5
163	Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis. 2019 , 24, 428-434		7
162	WITHDRAWN: Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance. 2019 , 74, 156-163		1
161	Case of both rivaroxaban- and dabigatran-induced leukocytoclastic vasculitis, during management of pulmonary thromboembolism. 2019 , 26, 219-222		7
160	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review. 2019 , 19, 243-244		2
159	Patients Prescribed Direct-Acting Oral Anticoagulants Have Low Risk of Postpolypectomy Complications. 2019 , 17, 2000-2007.e3		14
158	Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. 2019 , 48, 240-249		8
157	Rivaroxaban or Apixaban for Non-Valvular Atrial Fibrillation - Efficacy and Safety of Off-Label Under-Dosing According to Plasma Concentration. 2019 , 83, 991-999		14
156	Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-dabigatran surveillance. 2019 , 73, 507-514		16
155	Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation. 2019 , 7, 1574541		21

154	Time-driven activity-based cost analysis for outpatient anticoagulation therapy: direct costs in a primary care setting with optimal performance. 2019 , 22, 471-477	11
153	Optimization of Pharmacotherapy with Direct Oral Anticoagulants: the Need to Choose the Right Dosage Regimen. <i>Rational Pharmacotherapy in Cardiology</i> , 2019 , 15, 593-603	0.5
152	Comparative Effectiveness and Safety of Rivaroxaban in Adults With Nonvalvular Atrial Fibrillation. 2019 , 26, e679-e703	3
151	Outcome reporting from clinical trials of non-valvular atrial fibrillation treated with traditional Chinese medicine or Western medicine: a systematic review. 2019 , 9, e028803	5
150	Differences in outcomes between oral anticoagulation "new starters" and "switchers" in patients with nonvalvular atrial fibrillation: A pooled analysis of the AMADEUS and BOREALIS trials. 2019 , 35, 815-820	
149	Direct Oral Anticoagulants in Octogenarians With Atrial Fibrillation: It Is Never Too Late. 2019 , 73, 207-214	20
148	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. 2019 , 26, e671-e678	2
147	Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review. 2019 , 19, 27-36	13
146	Comparative effectiveness of direct oral anticoagulants versus low-molecular weight heparins for the prevention of venous thromboembolism after total hip or knee replacement: A nationwide database cohort study. 2019 , 141, 201-207	7
145	Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. 2019 , 36, 162-174	11
144	Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation. 2019 , 70, 61-75	6
143	Guideline-concordant initiation of oral anticoagulant therapy for stroke prevention in older veterans with atrial fibrillation eligible for Medicare Part D. 2019 , 54, 128-138	3
142	Differences in safety and efficacy of oral anticoagulants in patients with non-valvular atrial fibrillation: A Bayesian analysis. 2019 , 73, e13308	6
141	The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. 2019 , 73, e13285	7
140	Secular Trends in the Background of Intracerebral Hemorrhage from 2010 to 2015. 2019 , 28, 26-30	
139	Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance database linked to emergency department records within five areas - rationale and design of SACHA study. 2019 , 33, 443-462	7
138	Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study. 2019 , 19, 223-230	4
137	Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis. 2019 , 72, 305-316	13

136	A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. 2020 , 30, 86-90		20
135	Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation. 2020 , 27, e270-e2852		
134	Adherence to Anticoagulation and Risk of Stroke Among Medicare Beneficiaries Newly Diagnosed with Atrial Fibrillation. 2020 , 20, 199-207		13
133	Safety and effectiveness of reduced-dose apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A sub-analysis of the STANDARD study. 2020 , 75, 208-215		15
132	Validation of obesity coding among newly treated nonvalvular atrial fibrillation patients using an integrated electronic medical record and claims database. <i>Current Medical Research and Opinion</i> , 2020 , 36, 189-197	2.5	9
131	Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis. 2020 , 18, 792-799.e61		27
130	Drug interactions with oral anticoagulants in German nursing home residents: comparison between vitamin K antagonists and non-vitamin K antagonist oral anticoagulants based on two nested case-control studies. 2020 , 109, 465-475		6
129	Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS. 2020 , 20, 81-103		5
128	HAS-BLED score as a predictor of bleeding complications from catheter ablation of atrial fibrillation: A subanalysis of the Japanese Anti-Coagulation Regimen Exploration in AF Catheter Ablation Registries. 2020 , 75, 82-89		6
127	Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation. 2020 , 71, 32-38		9
126	Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and Rivaroxaban in atrial fibrillation. <i>Thrombosis Research</i> , 2020 , 185, 135-141	8.2	6
125	Stroke and thromboembolism prevention in atrial fibrillation. <i>Heart</i> , 2020 , 106, 10-17	5.1	23
124	Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents. 2020 , 58, 217-233		7
123	Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. 2020 , 23, 1389-1400		1
122	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020 , 22, 11-112	1.5	2
121	Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies. <i>TH Open</i> , 2020 , 4, e145-e152 ^{2.7}		9
120	Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA. 2020 , 37, 3942-3953		1
119	The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study. 2020 , 52, 529-538		3

118	Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: A retrospective cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1293-1320	2.6	2
117	Major bleeding risk associated with oral anticoagulant in real clinical practice. A multicentre 3-year period population-based prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 2519-2529	3.8	5
116	Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	5
115	Perceptions and Experiences of Atrial Fibrillation Patients on Their Condition and Oral Anticoagulant Treatment. 2020 , 9, 409-420		0
114	Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. 2020 , 9, 87-96		1
113	Simultaneous Determination of Dabigatran, Rivaroxaban, and Apixaban in Human Plasma by Liquid Chromatography/Tandem Mass Spectrometry. 2020 , 42, 473-480		5
112	Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. <i>Stroke</i> , 2020 , 51, 2066-2075	6.7	15
111	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. 2020 , 63, 8088-8113		7
110	Anticoagulation in AF and Elderly Frail Patient: How to Face New Challenges. 2020 ,		
109	Rivaroxaban as an Alternative Agent for Heparin-Induced Thrombocytopenia. 2020 , 60, 1362-1366		4
108	Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran. 2020 , 37, 3537-3550		4
107	Anticoagulants' Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study. 2020 , 18, 131-138		3
106	Effectiveness and Safety of Off-label Dosing of Non-vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients. 2020 , 10, 1801		15
105	Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants. 2020 , 50, 718-723		4
104	Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 75-85	6.4	28
103	Could the Novel Oral Anticoagulants Be Used for Coronary Artery Aneurysm?. 2020 , 2020, 5073814		3
102	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2020 , 26, 639-651	1.9	1
101	Retrospective review of D-dimer testing for venous thrombosis recurrence risk stratification: is this a useful test in the real world?. 2020 , 49, 562-571		2

100	Efficacy of 4-Factor Prothrombin Complex Concentrates in Factor Xa Inhibitor-Associated Intracranial Bleeding. 2021 , 34, 112-120		12
99	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 988-1000	3.8	3
98	Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. 2021 , 289, 42-52		14
97	All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, F93-F100	6.4	9
96	Influence of anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection: a multicenter retrospective study. <i>Gastric Cancer</i> , 2021 , 24, 179-189	7.6	8
95	Cessation of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Heart</i> , 2020 ,	5.1	
94	Incidence, predictors of bleeding and prognosis of bleeding in anticoagulated nonagenarian patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2021 , 327, 217-222	3.2	1
93	Comparative effectiveness and safety of non-vitamin-K antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes. <i>Current Medical Research and Opinion</i> , 2021 , 37, 343-358	3.5	1
92	A comprehensive appraisal of dabigatran etexilate clinical evidence and applications: a 10-year-long story. <i>Future Cardiology</i> , 2021 , 17, 215-226	1.3	1
91	Hematoma Risk After Needle Electromyography in Patients Using Newer Oral Anticoagulants. <i>Journal of Clinical Neurophysiology</i> , 2021 , 38, 69-72	2.2	2
90	Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 50-58	6.4	10
89	Anticoagulation in Elderly Patients with Atrial Fibrillation Authors. 2021 , 131-147		
88	Neurological complications of cardiovascular drugs. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2021 , 177, 319-344	3	1
87	Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials. <i>Annals of Gastroenterology</i> , 2021 , 34, 651-659	2.2	0
86	Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available "Real-World" Evidence: The Italian National Health System Perspective. <i>Clinical Drug Investigation</i> , 2021 , 41, 255-267	3.2	6
85	Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. <i>CNS Drugs</i> , 2021 , 35, 305-316	6.7	3
84	Bleeding and related mortality with NOACs and VKAs in newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry. <i>Blood Advances</i> , 2021 , 5, 1081-1091	7.8	8
83	[Atrial Fibrillation and Mortality: Prognostic Factors and Direction of Prevention]. <i>Kardiologiya</i> , 2021 , 61, 91-98	1.5	2

82	The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. <i>Medicine (United States)</i> , 2021 , 100, e25216	1.8	1
81	Employing AI with NLP to Combine EHR's Structured and Free Text Data to Identify NVAf to Decrease Strokes and Death (Preprint).		
80	Using Artificial Intelligence With Natural Language Processing to Combine Electronic Health Record's Structured and Free Text Data to Identify Nonvalvular Atrial Fibrillation to Decrease Strokes and Death: Evaluation and Case-Control Study. <i>Journal of Medical Internet Research</i> , 2021 , 23, e28946	7.6	1
79	Predicting major bleeding among hospitalized patients using oral anticoagulants for atrial fibrillation after discharge. <i>PLoS ONE</i> , 2021 , 16, e0246691	3.7	3
78	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 3508-3517	3.8	1
77	Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
76	Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. <i>World Journal of Cardiology</i> , 2021 , 13, 82-94	2.1	0
75	Gastrointestinal Bleeding and Direct Oral Anticoagulants among Patients with Atrial Fibrillation: Risk, Prevention, Management, and Quality of Life. <i>TH Open</i> , 2021 , 5, e200-e210	2.7	0
74	Importance of Paroxysmal Atrial Fibrillation and Sex Differences in the Prevention of Embolic Stroke in Hypertrophic Cardiomyopathy. <i>Circulation Reports</i> , 2021 , 3, 273-278	0.7	0
73	Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI). <i>Frontiers in Neurology</i> , 2021 , 12, 650695	4.1	2
72	Trends in Incidence of Intracerebral Hemorrhage and Association With Antithrombotic Drug Use in Denmark, 2005-2018. <i>JAMA Network Open</i> , 2021 , 4, e218380	10.4	2
71	Association of Type of Antidepressant Initiation with Bleeding Risk in Atrial Fibrillation Patients Taking Oral Anticoagulants. <i>Drugs - Real World Outcomes</i> , 2021 , 8, 383-391	2.2	0
70	Characteristics, Location, and Clinical Outcomes of Gastrointestinal Bleeding in Patients Taking New Oral Anticoagulants Compared to Vitamin K Antagonists. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
69	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a scandinavian population-based cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021 ,	4.6	0
68	Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study. <i>Thrombosis Research</i> , 2021 , 203, 121-130	8.2	2
67	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population-based cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1339-1352	2.6	4
66	Phase I clinical trial of an antithrombotic drug protocol combining apixaban and clopidogrel in dogs. <i>Journal of Veterinary Cardiology</i> , 2021 , 36, 105-114	1.9	1
65	Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding. <i>JAMA Network Open</i> , 2021 , 4, e2120064	10.4	5

64	Synergistic effect of matching corporate and product brand images on purchase intentions: Comparing the importance of functional and emotional value. <i>Journal of Brand Management</i> , 1	3.3	3
63	Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences. <i>Egyptian Heart Journal</i> , 2021, 73, 70	1.3	3
62	Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2021, 27, 1056-1066	1.9	1
61	Effectiveness and Safety of Dabigatran in Atrial Fibrillation Patients with Severe Obesity: a Real-World Retrospective Cohort Study. <i>Journal of General Internal Medicine</i> , 2021, 1	4	
60	Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients With Active Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 411-424	3.8	3
59	Stroke Prevention by Anticoagulants in Daily Practice Depending on Atrial Fibrillation Pattern and Clinical Risk Factors. <i>Stroke</i> , 2021, 52, 3121-3131	6.7	
58	MAC Project-Monitoring Anticoagulant Therapy Observational Study: Rationale and Protocol. <i>Frontiers in Medicine</i> , 2020, 7, 584459	4.9	1
57	Individualised Risk Assessments for Recurrent Venous Thromboembolism: New Frontiers in the Era of Direct Oral Anticoagulants. <i>Hemato</i> , 2021, 2, 64-78	0.2	0
56	Risk of Stroke and Bleeding in Atrial Fibrillation Treated with Apixaban Compared with Warfarin. <i>Journal of General Internal Medicine</i> , 2020, 35, 3597-3604	4	2
55	[Use of direct-acting oral anticoagulants in Primary Care in Spain. Positioning statement by SEMERGEN on the current situation]. <i>Semergen</i> , 2019, 45, 413-429	1.9	10
54	Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. <i>PLoS ONE</i> , 2017, 12, e0181000	3.7	22
53	Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. <i>PLoS ONE</i> , 2018, 13, e0191722	3.7	27
52	Atrial Fibrillation and Anticoagulation in Hypertrophic Cardiomyopathy. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 63-68	3.2	10
51	Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation. <i>Oncotarget</i> , 2017, 8, 98898-98917	3.3	5
50	Left Atrial Appendage Closure: A Safe and Effective Alternative to Anticoagulation?. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3486-3493	1.1	1
49	Apixaban: An Update of the Evidence for Its Place in the Prevention of Stroke in Patients with Atrial Fibrillation. <i>Core Evidence</i> , 2020, 15, 1-6	4.9	2
48	Profiling Clinical Characteristics and Treatment Patterns Among Non-Valvular Atrial Fibrillation Patients: A Real-World Analysis in Dubai, United Arab Emirates. <i>Open Medicine Journal</i> , 2019, 6, 33-41	0.5	6
47	Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. <i>Blood Transfusion</i> , 2020, 18, 486-495	3.6	5

46	Management of Stroke risk in atrial fibrillation patients with bleeding on Oral Anticoagulation Therapy-Role of Left Atrial Appendage Closure, Octreotide and more. <i>Journal of Atrial Fibrillation</i> , 2017 , 10, 1729	0.8	2
45	Critical Issues and Recent Advances in Anticoagulant Therapy: A Review. <i>Neurology India</i> , 2019 , 67, 1200-1212	1.7	3
44	Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Clinical Drug Investigation</i> , 2021 , 41, 941-953	3.2	0
43	The year in cardiology 2016: arrhythmias and cardiac implantable electronic devices. <i>Cardiologia Croatica</i> , 2017 , 12, 240-253	0	
42	Bleeding Risk under Oral Factor Xa Inhibitors: Meta-analysis of the randomized comparison with Vitamin K Antagonists and Meta-Regression analysis. <i>Journal of Cardiovascular Medicine and Cardiology</i> , 038-048	0.1	
41	Laboratory Tests in Assessing the Bleeding Risk in Patients Receiving Direct Oral Anticoagulants (DOACs). <i>World Journal of Cardiovascular Diseases</i> , 2018 , 08, 257-264	0	
40	Efficacy and safety of anticoagulation therapy in patients with non-valvular atrial fibrillation in actual clinical setting. <i>Nosotchu</i> , 2019 , 41, 85-92	0.1	0
39	Kardiologische Aspekte bei intrakraniellen Blutungen (ICB). 2019 , 71-85		
38	Novel Oral Anticoagulants [Do Real-world Data Support our Expectations?]. <i>European Journal of Arrhythmia & Electrophysiology</i> , 2019 , 5, 48	0.3	
37	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. <i>EGEMS (Washington, DC)</i> , 2019 , 7, 27	2.2	2
36	Identifying outcome measures for atrial fibrillation value-based contracting using the Delphi method. <i>Research in Social and Administrative Pharmacy</i> , 2021 ,	2.9	
35	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. <i>European Heart Journal Supplements</i> , 2020 , 22, O78-O86	1.5	5
34	Gastrointestinal Bleeding Associated With Warfarin and Rivaroxaban Therapy in Atrial Fibrillation Cases with Concomitant Coagulopathy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021 , 21, 123-127	1.1	
33	HEMATURIA AND OTHER KINDS OF BLEEDINGS ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION: AN UPDATED OVERVIEW ON OCCURRENCE, PATHOMECHANISMS AND MANAGEMENT. <i>Wiadomości Lekarskie</i> , 2020 , 73, 2528-2534	0.3	
32	Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2020 , 27, e28-e44	2	2
31	Gastrointestinal Bleeding: a Cardiologist's Point of View. <i>Rational Pharmacotherapy in Cardiology</i> , 2021 , 17, 771-778	0.5	
30	[Comparative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease]. <i>Kardiologiya</i> , 2020 , 60, 102-109	1.5	
29	A Real-world Experience of the Safety and Efficacy of Non-vitamin K Oral Anticoagulants Versus Warfarin in Patients with Non-valvular Atrial Fibrillation: A Single-centre Retrospective Cohort Study in Singapore. <i>Annals of the Academy of Medicine, Singapore</i> , 2020 , 49, 838-847	2.8	0

28	Evidence and uncertainties in the management of atrial fibrillation in older persons. <i>Minerva Medica</i> , 2021 ,	2.2	0
27	Brand Concept Rather Than Brand Image?: Consumer-Oriented Evaluation Items that Should Be Managed as Factors of Brand Loyalty. <i>Lecture Notes in Networks and Systems</i> , 2022 , 401-411	0.5	
26	The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics.. <i>European Journal of Epidemiology</i> , 2022 , 37, 95	12.1	1
25	Switching of oral anticoagulants in atrial fibrillation: a cohort study using Australian general practice data.. <i>Expert Review of Clinical Pharmacology</i> , 2022 ,	3.8	0
24	Can Machine Learning from Real-World Data Support Drug Treatment Decisions? A Prediction Modeling Case for Direct Oral Anticoagulants.. <i>Medical Decision Making</i> , 2021 , 272989X211064604	2.5	1
23	Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022 , 11, 3788	5.1	
22	Moderne Antikoagulation mit FXa-Inhibitoren in der Onkologie: Ist die gastrointestinale Blutungsrate (mit)-entscheidend?. <i>Zeitschrift Fur Gastroenterologie</i> ,	1.6	
21	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population: updated analysis. 1-10		
20	Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease. 2022 , 9, e002043		0
19	Nine-Year Trends in Prevention of Thromboembolic Complications in Elderly Patients with Atrial Fibrillation Treated with NOACs. 2022 , 19, 11938		0
18	Payer Formulary exclusions of apixaban: how patients respond and potential implications. 1-10		0
17	Impact of Integrating Machine Learning in Comparative Effectiveness Research of Oral Anticoagulants in Patients with Atrial Fibrillation. 2022 , 19, 12916		0
16	Gene set proximity analysis: expanding gene set enrichment analysis through learned geometric embeddings, with drug-repurposing applications in COVID-19.		0
15	Assessing medicines for use in the Geriatric Population.		1
14	Gastrointestinal Bleeding Due to NOACs Use: Exploring the Molecular Mechanisms. 2022 , 23, 13955		0
13	Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. 14, 576-598		0
12	Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity.		0
11	Stroke Prevention with Anticoagulant in Cardiovascular Problem: Focus in Atrial Fibrillation. 2023 , 269-292		0

- 10 Does Early Detection of Atrial Fibrillation Reduce the Risk of Thromboembolic Events? Rationale and Design of the Heartline Study. **2023**, ○
- 9 Direct Oral Anticoagulants for Stroke Prevention in Special Populations: Beyond the Clinical Trials. **2023**, 11, 131 ○
- 8 Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation. ○
- 7 Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. ○
- 6 Safety and Efficacy Re-Evaluation of Edoxaban and Rivaroxaban Dosing With Plasma Concentration Monitoring in Non-Valvular Atrial Fibrillation: With Observations of On-Label and Off-Label Dosing. **2023**, 5, 80-89 ○
- 5 Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study. 14, ○
- 4 Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients with Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. **2023**, 10, 65 ○
- 3 Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency. **2023**, 9, 109-118 ○
- 2 Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. **2023**, 37, 203-214 ○
- 1 Patterns and outcomes of switching direct oral anticoagulants in non-valvular atrial fibrillation: A real-world experience from Spain. **2023**, ○